Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dendreon Corporation (DNDN): Is Time Running Out for This Fallen Biotech?

Page 1 of 2

Dendreon Corporation (NASDAQ:DNDN)There’s a lot to notice from Johnson & Johnson (NYSE:JNJ)’s earnings — the company announced a very solid quarter. But the one thing that really stood out is the high sales that the company produced from its prostate cancer drug Zytiga. Does Zytiga’s succes further indicate that time is running out for Dendreon Corporation (NASDAQ:DNDN)’s Provenge?

Zytiga’s not slowing down

Johnson & Johnson (NYSE:JNJ)’s total sales for the quarter were $17.88 billion. But one of its largest segments, global pharmaceuticals — with $7 billion in sales — grew 12% year over year. The primary reason for this growth was the continued strength of new product launches from Xarelto (an anticoagulant), Incivo (which treats hepatitis C), and of course, Zytiga.

For the second quarter, sales of Zytiga were $395 million. This represents a 70% year-over-year gain for the blockbuster cancer drug. Furthermore, it represents 71% growth for the first six months of 2013.

Now, in regards to Johnson & Johnson (NYSE:JNJ)’s long-term stock performance, Zytiga has little meaning. Analysts project peak sales of $1.8 billion by 2015, which is fairly small in comparison to the company’s near $70 billion in annual revenue. However, these sales are crushing for Dendreon Corporation (NASDAQ:DNDN).

Connecting the dots

Dendreon Corporation (NASDAQ:DNDN) markets Provenge, which also targets late-stage prostate cancer patients. In 2011, it was one of the only drugs for this disease on the market, and analysts projected peak sales over $1 billion. However, analysts and investors have since feared how the company would respond to both Zytiga and Medivation Inc (NASDAQ:MDVN)’s new prostate cancer drug Xtandi.

Last quarter, for the first time since Provenge’s launch, sales of the drug declined year over year. The 17.6% decline was not expected, and management was honest about the impact of new competition. At the same time, while sales of Provenge were just $67.6 milllion, Zytiga’s sales grew more than 70% to $344 million. This showed a direct correlation between the declines of Provenge and the success of Zytiga.

Now, in this most recent quarter, sales of Zytiga have grown even more rapidly, at nearly $400 million. Therefore, common sense suggests more pain for Dendreon Corporation (NASDAQ:DNDN). Moreover, sales of Medivation Inc (NASDAQ:MDVN)’s Xtandi were $75.4 million in the U.S. alone. This represented an increase of $18 million over the prior quarter. This shows that both Xtandi and Zytiga are gaining traction, while Provenge may be seeing the beginning of its end.

Why is Provenge lagging?

Retail investors unfamiliar with the story might wonder why Provenge is falling behind. Also, why is Provenge stuck with annual sales of $311 million, while Zytiga and Xtandi have peak sales outlooks of $1.8 billion and $2.2 billion, respectively?

First, all three drugs treat advanced stages of prostate cancer, and all three extend life in a range of three to five months. However, Provenge is an immunotherapy, meaning it targets specific antigens that are expressed by the cancer. By attacking the antigen, the immune system can then work to fight the disease.

Xtandi and Zytiga work differently. They both work to stop the production of hormones that that aid in the growth of the tumor. Thus, while all three add life to patients, both Zytiga and Xtandi actually reduce the growth of tumors; Provenge does not.

Also, Provenge is significantly more expensive. It must be given in a hospital setting with an IV drip. It also requires a blood draw for each dose of Provenge, since the treatment can not be frozen or stored. Both Xtandi and Zytiga are in pill form, meaning no IV and fewer trips to the hospital with lower patient and physician costs. These advantages combined have led Xtandi and Zytiga to emerge as clear winners, while Provenge appears obsolete.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!